ICPT Stock Recent News

NASH, or nonalcoholic steatohepatitis, is a liver inflammatory disease that can progress to fibrosis and cirrhosis. NASH is now the second leading cause of liver transplantation, and the US patient population is forecast to increase from 16 million in 2015 to 27 million in 2030.

Intercept (ICPT) declines on news of a GIDAC meeting to discuss the NDA for the OCA for NASH in May.

Intercept (ICPT) gains 28.7% in the past 3 months on NDA's acceptance for NASH treatment and Ocaliva's performance.

Intercept Pharmaceuticals said Friday its experimental liver disease treatment will face an FDA panel in May, leading ICPT stock to tumble. The post Intercept Tumbles As Its Experimental NASH Drug Faces Yet Another Obstacle appeared first on Investor's Business Daily.

Intercept Pharmaceuticals said Friday its experimental liver disease treatment will face an FDA panel in May, leading ICPT stock to tumble. The post Intercept Tumbles As Its Experimental NASH Drug Faces Yet Another Obstacle appeared first on Investor's Business Daily.

MORRISTOWN, N.J., March 09, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it will be participating in investor meetings at the Barclays Global Healthcare Conference at the Loews Miami Beach Hotel on March 14, 2023.

Intercept (ICPT) posts a narrower loss in Q4 due to higher revenues.

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT ) Q4 2022 Results Conference Call March 2, 2023 8:30 AM ET Company Participants Nareg Sagherian - Executive Director, Investor Relations Jerry Durso - President and Chief Executive Officer Linda Richardson - Chief Commercial Officer Dr. Michelle Berrey - President, Research & Development and Chief Medical Officer Andrew Saik - Chief Financial Officer Conference Call Participants Ritu Baral - Cowen Mayank Mamtani - B. Riley Securities Jon Wolleben - JMP Securities Joseph Stringer - Needham & Company Brian Skorney - Baird Brian Abrams - RBC Capital Markets Jay Olson - Oppenheimer Eliana Merle - UBS Operator Good day and thank you for standing by.

Intercept (ICPT) delivered earnings and revenue surprises of 20.75% and 0.42%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Due to what is seemingly a successful comeback, you can expect Intercept Pharmaceuticals to potentially deliver several-fold returns. Ocaliva's revenue for PBC alone is nearly enough to bank a net profit.